Cross-species functional screening, long-term animal studies, and multi-omics reveal molecular mechanisms that promote healthspan.
From natural-product screening to DNA double-strand break repair and cancer vulnerabilities, we connect fundamental mechanisms with therapeutic strategies.
We integrate AI-assisted multi-omics, target prioritization, mechanistic validation, animal studies, and patent strategy to advance natural-product discoveries toward translation.
We integrate natural-product and drug screening, molecular and cellular biology, model organisms, long-term animal studies, multi-omics, and AI-assisted data integration across three connected research directions.
Beginning with yeast lifespan screening, we extend discoveries to human cells, model organisms, long-term mouse studies, and multi-organ multi-omics to determine how natural products influence healthspan, energy metabolism, mitochondrial function, and sex-specific biology.
We use functional screening to identify natural products that modulate DNA double-strand break repair, define their molecular pharmacology and cancer-cell repair vulnerabilities, and evaluate their potential to enhance chemotherapy and radiotherapy.
Our workflow spans candidate discovery, AI-assisted prioritization, target identification and mechanistic validation, in vivo functional assessment, and patent strategy, advancing basic discoveries toward testable interventions for disease and healthy aging.
We apply AI to multi-omics integration and drug discovery. AI-assisted analyses integrate high-dimensional RNA-seq, proteomic, acetylomic, and metabolomic datasets to identify consistent signals across tissues and omics layers, prioritize candidate targets, and generate experimentally testable mechanistic hypotheses.
For drug discovery, we combine molecular docking, structure-guided virtual screening, and AI-assisted prediction to analyze compound–target binding modes, prioritize candidate molecules, and guide subsequent structural optimization and mechanistic experiments. AI accelerates data integration, drug design, and candidate selection; all key conclusions remain subject to biochemical, cellular, molecular, and animal validation.